SCHEMBL25966341

SCHEMBL25966341

CC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](OCCOC)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 3/20 0.61
▸ ADORA3 P0DMS8 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ DPP4 P27487 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ SLC28A1 O00337 1/20 0.57
▸ MAP3K7 O43318 1/20 0.57
▸ SLC28A2 O43868 1/20 0.57
▸ GAPDH P04406 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ ADORA2A P29274 1/20 0.57
▸ ADORA2B P29275 1/20 0.57
▸ STAT6 P42226 1/20 0.57
▸ PI4KA P42356 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ PI4K2B Q8TCG2 1/20 0.57
▸ DOT1L Q8TEK3 1/20 0.57
▸ SLC29A1 Q99808 1/20 0.57
▸ PI4K2A Q9BTU6 1/20 0.57
▸ SLC28A3 Q9HAS3 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29408565 0.92 ADORA1 (0.72) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL21999787 0.92 ADORA1 (0.61) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL1060588 0.92 ADORA1 (0.72) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL26370816 0.92 ADORA1 (0.72) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL1060584 0.92 ADORA1 (0.72) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL28680450 0.92 ADORA1 (0.72) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL21344303 0.89 ADORA3 (0.65) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL18349672 0.89 ADORA1 (0.55) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL25966336 0.89 GAA (0.52) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL16587677 0.89 GAA (0.52) ADORA1ADORA3SMN1; SMN2DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS Janssen Biopharma, Inc. 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS NT5C3B, PNP, NME1 ADORA1 750/4885ADORA3 349/4885SMN1; SMN2 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback